Amrutanjan Health Care Ltd Q2 FY27 results (latest), Jul–Sep 2026 →Revenue ₹135 Cr +14.4% YoYSee revenue, profit and what management said. You are viewing Q1 FY27.
AH

Amrutanjan Health Care Ltd

Q1 FY27Pharmaceuticals & Biotechnology

Amrutanjan Health Care Q1 FY27 earnings call: Revenue & Margins

Q1 FY27 investor presentation: what the company reported on revenue, margins and capex.

Revenue
₹103Cr
+9.6% YoY
−31.3% QoQ
Net profit
₹4Cr
−50% YoY
−75% QoQ
Margin
6%
−3 pp YoY
−11 pp QoQ

Based on Amrutanjan Health Care Ltd's Q1 FY27 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.

Price₹510
Market cap₹1.4K Cr
P/E23.0

The short version

Net Sales Q1 FY27: Rs. 102.97 Cr, up 9.48% YoY (Rs. 94.05 Cr in Q1 FY26) [Page 15].

From Amrutanjan Health Care Ltd's Q1 FY27 earnings-call transcript · updated 24 Sept 2026.

Revenue & Sales Performance

- Net Sales Q1 FY27: Rs. 102.97 Cr, up 9.48% YoY (Rs. 94.05 Cr in Q1 FY26) [Page 15] - OTC Products Net Sales Q1 FY27: Rs. 57.26 Cr, slight growth from Rs. 56.97 Cr YoY [Page 16] - Comfy (Women’s Hygiene & Personal Care) Net Sales Q1 FY27: Rs. 33.80 Cr, up 18.14% YoY (Rs. 28.61 Cr in Q1 FY26) [Page 16] - Beverages Net Sales Q1 FY27: Rs. 8.64 Cr, up 11.34% YoY (Rs. 7.76 Cr in Q1 FY26) [Page 17] - Hydration Drinks Net Sales Q1 FY27: Rs. 8.04 Cr, up 13.88% YoY (Rs. 7.06 Cr in Q1 FY26) [Page 17] - Pain Management category volume growth Q1 FY27: -3.4% vs. +6.6% in Q1 FY26 [Page 20] - New launches (Razors & Plastry) revenue Q1 FY27: Rs. 3 Cr for razors, Rs. 1.12 Cr for Plastry; annual projection Rs. 15 Cr and Rs. 10 Cr respectively [Pages 20, 9] **Outlook:** - Confident of double-digit revenue and operating profit growth for FY27 [Page 21]

2 more points from Amrutanjan Health Care Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Amrutanjan Health Care Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • Commissioned a new Greenfield Sanitary Napkin Manufacturing Facility in Telangana.
  • Investment amount: ₹150 crore.
  • Facility size: Spread over 10 acres with 1.4 lakh sq. ft. built-up area.
  • Plant features two fully automated high-speed production lines from Japan.
  • This is Amrutanjan’s fifth manufacturing plant.
  • The facility is recently commissioned (as of the quarter ended 30th June 2026).
  • The plant aims to strengthen feminine hygiene product manufacturing under the Comfy brand.

2 more points from Amrutanjan Health Care Ltd's call on capex

Create a free account to keep reading this call

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
Rev 1Mar 1
2KRM Ayurveda
Rev 1Mar 1
3
Rev 1Mar 2
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Amrutanjan Health Care Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

See what Amrutanjan Health Care Ltd said on order book & pipeline — free account, 30 seconds.

Amrutanjan Health Care Ltd — Quarterly revenue & net profit

Revenue Net profit
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Amrutanjan Health Care Ltd Q1 FY27 results — key figures

Amrutanjan Health Care Ltd Q1 FY27 reported results vs Q1 FY26, ₹ crore
₹ CrQ1 FY27Q1 FY26YoYQ4 FY26QoQ
Revenue10394+9.6%150-31.3%
Operating profit (EBITDA)68-25%26-76.9%
Operating margin6%9%-3 pp17%-11 pp
Profit before tax611-45.5%21-71.4%
Net profit (PAT)48-50%16-75%
EPS (₹)1.512.87-47.4%5.60-73%

Source: reported quarterly figures (Screener), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹135 Cr, net profit ₹17 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Others in Pharmaceuticals & Biotechnology this season

  • KRM Ayurveda (Q1 FY27)

    Total income for Q1 FY27: ₹3,286.55 Lakhs, +32.4% YoY . Key investor presentation takeaways from KRM Ayurveda Ltd's Q1 FY27 investor presentation — and how it r

  • Balaxi Pharma (Q1 FY27)

    Q1 FY27 Revenue: ₹80.68 crore, up 14.1% YoY from ₹70.74 crore in Q1 FY26 (Page 20). Key investor presentation takeaways from Balaxi Pharma's Q1 FY27 investor pr

  • Sanjivani Paranteral (Q1 FY27)

    Q1 FY27 consolidated revenue from operations: ₹238.39 Mn, up 33.8% YoY from ₹178.92 Mn in Q1 FY26 (Page 25). Key investor presentation takeaways from Sanjivani

  • Natural Capsules (Q1 FY27)

    Revenue from Operations for Q1FY27: ₹48.71 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q1 FY27 investor presentation — and how it ra

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Amrutanjan Health Care Ltd and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Amrutanjan Health Care Ltd Q1 FY27 results?

Net Sales Q1 FY27: Rs. 102.97 Cr, up 9.48% YoY (Rs. 94.05 Cr in Q1 FY26) [Page 15].

What is Amrutanjan Health Care Ltd share price analysis?

Amrutanjan Health Care Ltd currently shows a neutral. The stock trades at a P/E of 22.9 with a market cap of ₹1,428 Cr. Investors should review the full earnings analysis for detailed insights.

Is Amrutanjan Health Care Ltd planning capital expenditure?

Commissioned a new Greenfield Sanitary Napkin Manufacturing Facility in Telangana. - Investment amount: ₹150 crore. - Facility size: Spread over 10 acres with 1.4 lakh sq.

Keep Amrutanjan Health Care Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.